Verve Therapeutics (NASDAQ:VERV) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Verve Therapeutics (NASDAQ:VERV - Free Report) from a sell rating to a hold rating in a research note issued to investors on Thursday morning.

Several other equities research analysts have also issued reports on VERV. Cantor Fitzgerald raised shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, April 15th. Canaccord Genuity Group boosted their price target on shares of Verve Therapeutics from $32.00 to $39.00 and gave the company a "buy" rating in a report on Tuesday, April 15th. Guggenheim boosted their price target on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a report on Tuesday, April 15th. Royal Bank of Canada lowered their price target on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Finally, William Blair reissued an "outperform" rating on shares of Verve Therapeutics in a report on Friday, February 21st. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $25.75.

Verve Therapeutics Trading Up 0.3%

NASDAQ VERV traded up $0.02 during trading on Thursday, reaching $4.38. The company's stock had a trading volume of 1,378,547 shares, compared to its average volume of 1,861,963. The stock has a market capitalization of $390.00 million, a PE ratio of -1.77 and a beta of 1.82. The business has a 50-day moving average price of $4.58 and a 200-day moving average price of $5.79. Verve Therapeutics has a 1-year low of $2.86 and a 1-year high of $9.31.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.36. The firm had revenue of $32.98 million during the quarter, compared to analysts' expectations of $7.13 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. As a group, analysts expect that Verve Therapeutics will post -2.49 earnings per share for the current year.

Institutional Investors Weigh In On Verve Therapeutics

Large investors have recently made changes to their positions in the company. KFG Wealth Management LLC bought a new stake in shares of Verve Therapeutics in the 1st quarter worth about $46,000. IFP Advisors Inc grew its holdings in shares of Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock worth $47,000 after purchasing an additional 8,237 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Verve Therapeutics in the 1st quarter worth about $47,000. E Fund Management Co. Ltd. bought a new stake in shares of Verve Therapeutics in the 1st quarter worth about $48,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Verve Therapeutics in the 4th quarter worth about $50,000. Institutional investors own 97.11% of the company's stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.